RHINIFIX NASAL SPRAY SUSPENSION 27.5 MICROGRAMS/SPRAY [SIN17626P]
Active ingredients: FLUTICASONE FUROATE
Product Info
RHINIFIX NASAL SPRAY SUSPENSION 27.5 MICROGRAMS/SPRAY
[SIN17626P]
Product information
Active Ingredient and Strength | FLUTICASONE FUROATE - 27.5 MCG/SPRAY |
Dosage Form | SPRAY, SUSPENSION |
Manufacturer and Country | CURIDA AS - NORWAY |
Registration Number | SIN17626P |
Licence Holder | NOVEM HEALTHCARE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | R01AD12 |
Prescription-only Medicines with Exemptions for Supply without Prescription | As an intranasal spray not exceeding 27.5 mcg/actuation
|
Indication
4.1 Therapeutic indications
Rhinifix is indicated for the treatment of the symptoms of allergic rhinitis in patients 2 years of age and older.
Dosing
4.2 Posology and method of administration
Rhinifix is for administration by the intranasal route only. For full therapeutic benefit regular scheduled usage is recommended. Onset of action has been observed as early as 8 hours after initial administration. It may take several days of treatment to achieve maximum benefit. An absence of an immediate effect should be explained to the patient (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Populations
For the treatment of seasonal allergic rhinitis and perennial allergic rhinitis:
Adults and Adolescents (12 years and older)
The recommended starting dosage is 2 sprays (27.5 micrograms per spray) in each nostril once daily (total daily dose, 110 micrograms).
Once adequate control of symptoms is achieved, dose reduction to 1 spray in each nostril once daily (total daily dose, 55 micrograms) may be effective for maintenance.
Children (2 to 11 years)
The recommended starting dosage is 1 spray (27.5 micrograms per spray) in each nostril once daily (total daily dose, 55 micrograms).
Patients not adequately responding to 1 spray in each nostril once daily (total daily dose, 55 micrograms) may use 2 sprays in each nostril once daily (total daily dose, 110 micrograms). Once adequate control of symptoms is achieved, dose reduction to 1 spray in each nostril once daily (total daily dose, 55 micrograms) is recommended.
Children (under 2 years of age)
There are no data to recommend use of intranasal fluticasone furoate for the treatment of seasonal or perennial allergic rhinitis in children under 2 years of age.
Elderly
No dosage adjustment required (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Renal impairment
No dosage adjustment required (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hepatic impairment
No dosage adjustment is required in patients with hepatic impairment (see section 4.4 and section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
